Funded Biotechnology Startups in Zürich
Disclosed funding in this Zurich biotechnology set clusters tightly below the top end: the largest disclosed round is Molecular Partners at $20M (2024-10-2…
Disclosed funding in this Zurich biotechnology set clusters tightly below the top end: the largest disclosed round is Molecular Partners at $20M (2024-10-25), while several other disclosed entries sit far lower, including Sequana Medical at $2M (2025-12-05), Trilliome at $60K (2025-10-16), and multiple $2M seeds/pre-seeds (CellX Biosolutions on 2025-02-25; Oncobit on 2024-11-11; IDUN Technologies on 2021-09-02). The other standout disclosed figure is Hemotune at $16M (2024-03-25) and BC Platforms at $20M (2022-11-08) and Araris Biotech at $24M (2022-10-04), with the $24M level noticeably above the rest of the disclosed amounts.
Timing and classification add another pattern. Rounds span 2021-09-02 (IDUN Technologies) through 2026-04-23 (SentiaNova), with a recent run of activity in 2025 (Sequana Medical on 2025-12-05; Trilliome on 2025-10-16; SEITO Biologics on 2025-06-11; CellX Biosolutions on 2025-02-25). Zurich is the dominant geography (all listed entries are in Zurich, Zurich, Switzerland except TOLREMO therapeutics and the address for Relief Therapeutics, both shown as Zurich), and classifications show frequent ambiguity: 2 entries are “undisclosed” (SentiaNova 2026-04-23; Arktis Radiation Detectors 2025-04-23) and 7 entries are labeled “Series Unknown” (Sequana Medical 2025-12-05; Trilliome 2025-10-16; Arktis Radiation Detectors 2025-04-23; Molecular Partners 2024-10-25; Relief Therapeutics 2023-06-16; Recolony 2023-02-21; BC Platforms 2022-11-08).
Most recent rounds
19 shownRelated listings
Frequently asked
What’s the largest disclosed round in this Zurich biotech list, and is it a true outlier versus the rest?
Araris Biotech’s $24M (2022-10-04) is the largest disclosed amount in the rows shown. Even the next-highest disclosed figure is $20M (Molecular Partners on 2024-10-25 and BC Platforms on 2022-11-08), which is meaningfully lower than $24M, while many other disclosed rounds cluster around $2M (e.g., CellX Biosolutions 2025-02-25; Oncobit 2024-11-11; IDUN Technologies 2021-09-02).
How often is funding classification ambiguous (Series Unknown or undisclosed), and what does that imply for deal comparability?
Seven entries are tagged “Series Unknown” (Sequana Medical 2025-12-05; Trilliome 2025-10-16; Arktis Radiation Detectors 2025-04-23; Molecular Partners 2024-10-25; Relief Therapeutics 2023-06-16; Recolony 2023-02-21; BC Platforms 2022-11-08) and 2 are “undisclosed” (SentiaNova 2026-04-23; Arktis Radiation Detectors 2025-04-23). That combination makes direct stage-to-stage comparisons less reliable across the set than a list with consistent round labels.
Are there clear temporal clusters among the most recent rounds?
Yes. Five of the 19 entries have 2025 round dates: Sequana Medical (2025-12-05), Trilliome (2025-10-16), SEITO Biologics (2025-06-11), Arktis Radiation Detectors (2025-04-23), and CellX Biosolutions (2025-02-25). That concentration contrasts with the earlier spread, including the oldest shown round at IDUN Technologies on 2021-09-02 and only two entries in 2021–2022 each beyond 2022-01-26 (Xlife Sciences AG).
Which stage labels show up repeatedly enough to be worth targeting, even with some entries marked Unknown?
Across the 19 rows, “Seed” appears multiple times (SEITO Biologics 2025-06-11 at $3M; Oncobit 2024-11-11 at $2M; Invasight 2022-06-07 at $5M; IDUN Technologies 2021-09-02 at $2M). “Series A” also repeats (Microcaps 2024-06-05 at $10M; TOLREMO therapeutics 2023-09-20 at $4M; Araris Biotech 2022-10-04 at $24M), which suggests investors and targets may be more concentrated around these early-to-mid stages than around rarer labels like Grant (MetrioPharm 2022-10-12 at $120K).
Which entries are the low-end disclosed outliers that could distort averages?
Trilliome’s $60K (2025-10-16) and MetrioPharm’s $120K (2022-10-12) sit far below most other disclosed rounds, including several $2M rounds (Sequana Medical at $2M on 2025-12-05; CellX Biosolutions at $2M on 2025-02-25; Oncobit at $2M on 2024-11-11; IDUN Technologies at $2M on 2021-09-02). Because these are orders of magnitude under the largest disclosed amounts ($24M and $20M), they can materially pull down any simple mean of disclosed deal sizes.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.